

Riccardo Giampieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1122073/publications.pdf>

Version: 2024-02-01

57
papers

980
citations

471061

17
h-index

476904

29
g-index

59
all docs

59
docs citations

59
times ranked

2072
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin-like growth factor 1 expression correlates with clinical outcome in KRAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	2.3	67
2	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. <i>Gastric Cancer</i> , 2017, 20, 156-163.	2.7	62
3	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. <i>Molecules</i> , 2014, 19, 6393-6406.	1.7	56
4	The Role of HER3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. <i>Oncologist</i> , 2011, 16, 53-60.	1.9	55
5	Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. <i>Frontiers in Oncology</i> , 2019, 9, 874.	1.3	48
6	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	45
7	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	0.8	40
8	<p></p>Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management<p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9363-9374.	0.9	40
9	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e72843.	1.1	36
10	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116.	2.0	33
11	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	2.7	32
12	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 272-283.	2.0	27
13	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	1.6	25
14	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. <i>Oncotarget</i> , 2015, 6, 38737-38748.	0.8	25
15	Clinical impact of different exosomes™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0215990.	1.1	24
16	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	1.6	22
17	BRAF-mutant colorectal cancer, a different breed evolving. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 499-512.	1.5	19
18	Prognostic Value for Incidental Antihypertensive Therapy With ð²-Blockers in Metastatic Colorectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e719.	0.4	18

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e601-e615.	1.0	18
20	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. <i>Pharmacogenomics</i> , 2013, 14, 1991-1998.	0.6	17
21	<p>Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 663-672.	0.9	17
22	Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102974.	2.0	17
23	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 934-941.	3.4	16
24	Optimal management of resected gastric cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1605-1618.	0.9	16
25	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 69.	1.3	16
26	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e38192.	1.1	15
27	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	1.7	15
28	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. <i>PLoS ONE</i> , 2013, 8, e78544.	1.1	14
29	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1"Final results of the ALICE-2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	0.8	13
30	Seroprevalence of SARS-CoV-2"Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1503.	1.0	12
31	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	2.0	11
32	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. <i>SpringerPlus</i> , 2015, 4, 743.	1.2	10
33	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	1.1	10
34	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 565-580.	0.9	10
35	New Insights into Hormonal Therapies in Uterine Sarcomas. <i>Cancers</i> , 2022, 14, 921.	1.7	10
36	Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. <i>Lung Cancer</i> , 2020, 146, 318-326.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 55.	0.5	9
38	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. <i>Frontiers in Oncology</i> , 2021, 11, 736104.	1.3	8
39	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2014, 15, 1225-1230.	1.0	7
40	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2015, 13, 140.	1.8	6
41	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	0.5	6
42	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	1.0	5
43	Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. <i>Cancers</i> , 2020, 12, 2724.	1.7	5
44	BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2021, 13, 5741-5751.	0.6	5
45	Maintenance therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1281-1282.	5.1	2
46	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. <i>Current Oncology</i> , 2021, 28, 3525-3536.	0.9	2
47	A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay. <i>Familial Cancer</i> , 2018, 17, 215-224.	0.9	1
48	Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Related Hypokalaemia. <i>Oncology and Therapy</i> , 2020, 8, 161-169.	1.0	1
49	An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer. <i>Oncology Letters</i> , 2021, 21, 267.	0.8	1
50	Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
51	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. <i>Anticancer Research</i> , 2015, 35, 2391-9.	0.5	1
52	Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO). <i>Supportive Care in Cancer</i> , 2021, 29, 851-858.	1.0	0
53	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 449-449.	0.8	0
54	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15126-e15126.	0.8	0

#	ARTICLE	IF	CITATIONS
55	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiALdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15116-e15116.	0.8	0
56	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16301-e16301.	0.8	0
57	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4153-4153.	0.8	0